Essential thrombocythemia and polycythemia vera: focus on clinical practice
Bone marrow (BM) morphologic features remain the cornerstone of diagnosis in both
essential thrombocythemia (ET) and polycythemia vera (PV). In addition, recently discovered …
essential thrombocythemia (ET) and polycythemia vera (PV). In addition, recently discovered …
Myeloproliferative neoplasms in children
I Hofmann - Journal of hematopathology, 2015 - Springer
Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell
disorders characterized by aberrant proliferation of one or more myeloid lineages often with …
disorders characterized by aberrant proliferation of one or more myeloid lineages often with …
A comprehensive review of pacritinib in myelofibrosis
S Verstovsek, RS Komrokji - Future Oncology, 2015 - Taylor & Francis
The first-in-class JAK1/JAK2 inhibitor ruxolitinib inhibits JAK/STAT signaling, inducing
durable reductions in splenomegaly and constitutional symptoms in patients with …
durable reductions in splenomegaly and constitutional symptoms in patients with …
Ni-Catalyzed C–H Functionalization in the Formation of a Complex Heterocycle: Synthesis of the Potent JAK2 Inhibitor BMS-911543
MA Fitzgerald, O Soltani, C Wei, D Skliar… - The Journal of …, 2015 - ACS Publications
BMS-911543 is a complex pyrrolopyridine investigated as a potential treatment for
myeloproliferative disorders. The development of a short and efficient synthesis of this …
myeloproliferative disorders. The development of a short and efficient synthesis of this …
How we diagnose and treat essential thrombocythaemia
S Alimam, BS Wilkins… - British journal of …, 2015 - Wiley Online Library
The approach to the diagnosis and management of essential thrombocythaemia (ET) is
steadily changing, influenced by advances in molecular biology, data from clinical trials and …
steadily changing, influenced by advances in molecular biology, data from clinical trials and …
Management of hematologic malignancies: special considerations in pregnant women
O Amit, M Barzilai, I Avivi - Drugs, 2015 - Springer
The diagnosis and management of hematologic malignancy during pregnancy is a
significant challenge. This is due to both medical and ethical considerations regarding when …
significant challenge. This is due to both medical and ethical considerations regarding when …
Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study
T Derlin, H Alchalby, P Bannas, S Veldhoen… - European journal of …, 2015 - Springer
Purpose Myelofibrosis is a haematopoietic stem cell neoplasm characterized by bone
marrow inflammation, reactive marrow fibrosis and extramedullary haematopoiesis. The aim …
marrow inflammation, reactive marrow fibrosis and extramedullary haematopoiesis. The aim …
How we manage JAK inhibition in allogeneic transplantation for myelofibrosis
TJ Ballinger, BN Savani, V Gupta… - European Journal of …, 2015 - Wiley Online Library
Hematopoietic stem cell transplantation (HCT) is currently the only curative treatment for
myelofibrosis (MF), but this option is complicated by high incidences of associated morbidity …
myelofibrosis (MF), but this option is complicated by high incidences of associated morbidity …
Современные подходы к диагностике и лечению эссенциальной тромбоцитемии: обзор литературы и собственные данные
КМ Абдулкадыров, ВА Шуваев… - Клиническая …, 2015 - cyberleninka.ru
Цель. Обзор литературы с освещением вопросов эпидемиологии, терминологии,
этиологии, механизмов становления и развития эссенциальной тромбоцитемии, а …
этиологии, механизмов становления и развития эссенциальной тромбоцитемии, а …
Pacritinib: a new agent for the management of myelofibrosis?
Y Beauverd, DP McLornan… - Expert Opinion on …, 2015 - Taylor & Francis
Introduction: Myelofibrosis (MF) is a clonal haematological disease associated with recurrent
somatic gene mutations (JAK2 V617F, MPL, CALR) and constitutive activation of the Janus …
somatic gene mutations (JAK2 V617F, MPL, CALR) and constitutive activation of the Janus …